Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

DAEWOONG PHARMA Logo
A global R&D partner for drug development, manufacturing, and commercialization services.
South Korea
069620
DAIICHI SANKYO COMPANY, LIMITED Logo
A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.
Japan
4568
Daito Pharmaceutical Co., Ltd. Logo
Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.
Japan
4577
Dare Bioscience, Inc. Logo
Advancing innovative therapies for women's health in contraception, fertility, and sexual health.
United States of America
DARE
Day One Biopharmaceuticals, Inc. Logo
Developing targeted cancer therapies for all ages, with a focus on pediatric oncology.
United States of America
DAWN
DBV Technologies Logo
Developing non-invasive skin patch immunotherapy for severe food allergies like peanut and milk.
France
DBV
DBV Technologies S.A. Logo
Developing non-invasive skin patch immunotherapies for food allergies and immune diseases.
United States of America
DBVT
D&D Pharmatech Inc. Logo
Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.
South Korea
347850
Dechra Pharmaceuticals PLC Logo
Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.
United Kingdom
DPH
DELCATH SYSTEMS, INC. Logo
Develops targeted chemotherapy delivery systems for treating primary and metastatic liver cancers.
United States of America
DCTH

Talk to a Data Expert

Have a question? We'll get back to you promptly.